PMID- 36971190
OWN - NLM
STAT- MEDLINE
DCOM- 20230504
LR  - 20230504
IS  - 1346-8138 (Electronic)
IS  - 0385-2407 (Linking)
VI  - 50
IP  - 5
DP  - 2023 May
TI  - Research progress of omalizumab in the treatment of bullous pemphigoid.
PG  - 575-587
LID - 10.1111/1346-8138.16791 [doi]
AB  - Bullous pemphigoid (BP) is an autoimmune blistering disease associated with 
      anti-BP180 and anti-BP230 antibodies. The pathogenic action mechanism of 
      immunoglobulin E (IgE) antibodies in BP has been studied since the 1970s, and IgE 
      antibodies have gradually been confirmed as being important in BP; therefore, 
      anti-IgE therapy may be a new option for the treatment of BP. Omalizumab, as an 
      IgE monoclonal antibody, has been increasingly used clinically to treat BP in 
      recent years. Here, we collected 35 papers investigating omalizumab for BP 
      treatment in a total of 83 patients, and the vast majority of patients showed 
      varying degrees of improvement after treatment, except for a small number of 
      patients with poor clinical outcomes. The patients were then divided into three 
      groups according to dosing frequency and number of doses. Statistical analysis 
      indicated that dosing frequency had little effect on clinical efficacy. While the 
      groups with different numbers of doses were evaluated, the results concluded that 
      clinical efficacy was affected by the number of doses, but there was no positive 
      correlation between the number of doses and clinical efficacy.
CI  - (c) 2023 Japanese Dermatological Association.
FAU - Ling, Xiaoya
AU  - Ling X
AD  - The First Clinical Medical College of Zhejiang Chinese Medicine University, 
      310053, Hangzhou, China.
FAU - Shou, Xinyang
AU  - Shou X
AD  - The First Clinical Medical College of Zhejiang Chinese Medicine University, 
      310053, Hangzhou, China.
FAU - Lou, Yufei
AU  - Lou Y
AD  - The First Clinical Medical College of Zhejiang Chinese Medicine University, 
      310053, Hangzhou, China.
FAU - Ling, Jie
AU  - Ling J
AD  - The First Clinical Medical College of Zhejiang Chinese Medicine University, 
      310053, Hangzhou, China.
FAU - Zhang, Mengyuan
AU  - Zhang M
AD  - The First Clinical Medical College of Zhejiang Chinese Medicine University, 
      310053, Hangzhou, China.
FAU - Yu, Tugen
AU  - Yu T
AD  - The First Affiliated Hospital of Zhejiang University of Traditional Chinese 
      Medicine (Zhejiang Province Hospital of Chinese Medicine), Hangzhou, 310006, 
      China.
FAU - Gu, Weijia
AU  - Gu W
AUID- ORCID: 0000-0003-2613-0981
AD  - School of Public Health, Zhejiang Chinese Medical University, Hangzhou, 310053, 
      China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230327
PL  - England
TA  - J Dermatol
JT  - The Journal of dermatology
JID - 7600545
RN  - 2P471X1Z11 (Omalizumab)
RN  - 0 (Autoantibodies)
RN  - 0 (Autoantigens)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - 0 (Non-Fibrillar Collagens)
SB  - IM
MH  - Humans
MH  - *Pemphigoid, Bullous
MH  - Omalizumab/therapeutic use
MH  - Autoantibodies
MH  - Autoantigens
MH  - Immunoglobulin E
MH  - *Autoimmune Diseases/drug therapy
MH  - Non-Fibrillar Collagens
OTO - NOTNLM
OT  - bullous pemphigoid
OT  - dosing frequency
OT  - immunoglobulin E
OT  - number of doses
OT  - omalizumab
EDAT- 2023/03/28 06:00
MHDA- 2023/05/04 12:41
CRDT- 2023/03/27 06:13
PHST- 2023/03/01 00:00 [revised]
PHST- 2023/01/14 00:00 [received]
PHST- 2023/03/10 00:00 [accepted]
PHST- 2023/05/04 12:41 [medline]
PHST- 2023/03/28 06:00 [pubmed]
PHST- 2023/03/27 06:13 [entrez]
AID - 10.1111/1346-8138.16791 [doi]
PST - ppublish
SO  - J Dermatol. 2023 May;50(5):575-587. doi: 10.1111/1346-8138.16791. Epub 2023 Mar 
      27.